Accession Therapeutics Ltd.

https://www.accessiontherapeutics.com

Accession Therapeutics is developing novel immune-oncology therapeutics combining high specificity and potency with the ability to counter tumour diversity. Led by T cell receptor therapy pioneer Bent Jakobsen, PhD FMedSci, the company is leveraging its Trocept platform technology to develop a portfolio of next generation products to the IND/early clinical trial stage. By engineering viruses specifically directed to cancer cells and carrying a transgene coding for an antitumour or immune activator drug, Trocept products are expected to be highly specific, broad in action so as to kill all cancer cell variants present in a tumour, and potent in activating the full immune system arsenal. The effects of the antitumour drug and immune system activation caused by cancer cell lysis after viral infection combine synergistically to give this broad and potent response, as illustrated in the animation here: https://bit.ly/3r8WgPu Dr Jakobsen is a founder of Adaptimmune and Immunocore which are both now listed on NASDAQ. Accession Therapeutics is backed by iGlobe Partners, Primavera Venture Partners, Birk Venture and other international biotech investors. It is based at ARC Oxford in the UK. *

	Start	2020-12-15 established
	Group	Accession Therapeutics (Group)
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Industry 2	Trocept technology platform
	Person	Jakobsen, Bent (Accession Therapeutics 202109– CEO before Adaptimmune + Immunocore + Avidex + IMM Oxford)
	Person 2	Robinson, Hans Ivar (Zelluna 201911 Board Chairman)

	Region	Abingdon, Oxfordshire
	Country	United Kingdom (GB)
	Street	Curch Lane Lashford House, Dry Sandford
	City	OX13 6JP Abingdon, Oxfordshire
		Address record changed: 2021-09-26

Basic data	Employees	n. a.

		* Document for »About Section«: Accession Therapeutics Ltd.. (11/21/22). "Press Release: Accession Therapeutics Raises £16.6m to Advance Potent Immunotherapies towards Clinical Trials". Oxford.

		Record changed: 2024-01-20